Treats amblyopia 1.1 Mydriasis 1.2 Cycloplegia 1.3 Penalization of the healthy eye in the…. ANDA 217791, held by Somerset. Atropine Sulfate.
As of Nov 16, 2026, ANDA 217791 (Atropine Sulfate), held by Somerset, was first approved by FDA on Apr 29, 2024, with 0 approved supplements and 0 published complete response letters.
Atropine sulfate ophthalmic solution 1% is indicated for: Atropine sulfate ophthalmic solution 1% is a muscarinic antagonist indicated for: Mydriasis Cycloplegia Penalization of the healthy eye in the treatment of amblyopia 1.1 Mydriasis 1.2 Cycloplegia 1.3 Penalization of the healthy eye in the treatment of amblyopia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2024 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atropine Sulfate1% · solution/drops;ophthalmic | Atropine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters